TABLE 2.
Competitor | Ki (10−9 M) |
---|---|
FXIa | 1.4 ± 0.28 |
FXI | NE |
rFXIa/PKA3 | 2.7 ± 0.32 |
rFXI/PKA3 | NE |
TRP383-LEU397 (peptide 1) | NE |
PHE415-GLY429 (peptide 2) | NE |
GLN433-GLU447 (peptide 3) | NE |
ILE450-ALA446 (peptide 4) | ND |
LYS467-ILE481 (peptide 5) | NE |
GLY500-LEU514 (peptide 6) | NE |
CYS527-CYS542 (peptide 7)* | 5.8 ± 0.78 |
CYS527-CYS542 (peptide 8)*† scr | NE |
Heavy Chain | NE |
Catalytic Domain | 3.5 ± 0.42 |
Denotes a cyclized peptide
scr denotes scrambled peptide
NE denotes no effect of the ligand at concentrations of up to 200 nM for FXI and rFXI/PKA3, up to 1 μM for the heavy chain, 100 μM for peptides 1–3, 5–6, and 1 μM for peptide 8.
ND denotes a value that was not determined.
Values represent the mean ± standard deviation for three independently performed experiments each carried out in triplicate.